Barclays PLC increased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 101.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 255,883 shares of the company's stock after buying an additional 128,823 shares during the period. Barclays PLC owned about 0.18% of Denali Therapeutics worth $7,454,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of DNLI. CWM LLC boosted its holdings in shares of Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company's stock valued at $63,000 after acquiring an additional 654 shares during the period. Quest Partners LLC acquired a new position in Denali Therapeutics during the 3rd quarter valued at about $73,000. Assetmark Inc. grew its position in Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company's stock worth $111,000 after purchasing an additional 580 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock valued at $152,000 after purchasing an additional 920 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Denali Therapeutics during the second quarter valued at approximately $194,000. Institutional investors own 92.92% of the company's stock.
DNLI opened at $21.43 on Thursday. The business has a fifty day simple moving average of $26.14 and a 200-day simple moving average of $24.92. The firm has a market cap of $3.08 billion, a PE ratio of -7.76 and a beta of 1.35. Denali Therapeutics Inc. has a fifty-two week low of $14.56 and a fifty-two week high of $33.33.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period in the previous year, the firm earned ($0.72) earnings per share. On average, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.
DNLI has been the topic of several recent analyst reports. Jefferies Financial Group lifted their target price on Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Friday, November 1st. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Denali Therapeutics in a report on Thursday, November 7th. Bank of America raised their target price on shares of Denali Therapeutics from $25.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. JPMorgan Chase & Co. reduced their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating for the company in a research note on Friday, October 11th. Finally, Raymond James reiterated a "market perform" rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $40.40.
View Our Latest Analysis on DNLI
In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the firm's stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the sale, the director now directly owns 29,096 shares in the company, valued at approximately $844,656.88. This trade represents a 50.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Vicki L. Sato sold 1,020 shares of Denali Therapeutics stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now directly owns 111,056 shares in the company, valued at approximately $3,331,680. This trade represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 86,578 shares of company stock worth $2,474,440 over the last 90 days. 7.90% of the stock is owned by company insiders.
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.